Earnings Releases

FRACTYL HEALTH, INC. reported the quarter ended March 31, 2026 results: net income $9.2 million. Guidance reaffirmed.

“Fractyl Health, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026”

System1, Inc. reported first quarter ended March 31, 2026 results: revenue Revenue of $37.2 million, net income GAAP Net Loss of $57.6 million.

“System1 Announces First Quarter 2026 Financial Results • Revenue of $37.2 million • GAAP Gross Profit of $23.3 million, Margin of 63% • Adjusted Gross Profit of $28.2 million, Margin of 76% • GAAP Net Loss of $57.6 million • Adjusted EBITDA of $2.7 million”

Nuwellis, Inc. reported the first quarter ended March 31, 2026 results: revenue $2.4 million, net income approximately $4.3 million.

“for patients with cardiorenal conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter and Recent Highlights: • Net sales were $2.4 million, a 26% increase compared to the prior-year period • Gross margin improved to 70.1%, reflecting improved pricing, product mix, and the transition to contract manufacturing •”

Nkarta, Inc. reported first quarter ended March 31, 2026 results: net income $27.8 million, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share. Guidance reaffirmed.

“Nkarta, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.”

TriSalus Life Sciences, Inc. reported the quarter ended March 31, 2026 results: revenue $8.9 million, net income $1.5 million, EPS $0.03.

“Revenue from the sale of the TriNav system, was $8.9 million for the three months ended March 31, 2026, a decrease of 2.9% compared to the same period in 2025.”

CURIS INC reported for the quarter ended March 31, 2026 results: net income net loss of $24.2 million, or $1.25 per share on both a basic and diluted basis, EPS $1.25 per share on both a basic and diluted basis.

“On May 12, 2026, Curis, Inc. announced its financial results for the three-month periods ended March 31, 2026.”

Velo3D, Inc. reported first quarter ended March 31, 2026 results: revenue $13.8 million, net income ($7.0), EPS ($0.28). Guidance reaffirmed.

“Velo3D Announces First Quarter 2026 Financial Results • Revenue of $13.8 million, up 48% year-over-year • Gross margin of 17.2% • Reaffirms outlook for 2026 revenue between $60 million and $70 million and to turn EBITDA positive in the second half of 2026 FREMONT, Calif., May 12, 2026 - Velo3D, Inc. (Nasdaq: VELO) (“Velo3D” or the “Company”), a leader in additive manufacturing (“AM”) technology known for transforming aerospace and defense supply chains through world-class metal AM, today announced financial results for its first quarter ended March 31, 2026.”

Smart Sand, Inc. reported first quarter ended March 31, 2026 results: revenue $93.1 million, net income $(3.9) million, EPS $(0.10) per basic and diluted share.

“otherwise be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Smart Sand, Inc. Announces First Quarter 2026 Results • 1Q 2026 revenue of $93.1 million • 1Q 2026 net loss of $(3.9) million • 1Q 2026 cash flow provided by operations of $3.0 million • 1Q 2026 contribution margin $13.2 million • 1Q 2026 Adjusted EBITDA of $3.8”

NETWORK-1 TECHNOLOGIES, INC. reported the quarter ended March 31, 2026 results: revenue no revenue, net income nil, EPS nil.

“Network-1 reported no revenue for the three months ended March 31, 2026”

Bright Mountain Media, Inc. reported first quarter ended March 31, 2026 results: revenue approximately $14.0 million, net income $1.3 million.

“Revenue was approximately $14.0 million, a slight decrease of $227,000, or 2%, compared to $14.2 million for the same period of 2025.”

KOPIN CORP reported first quarter ended March 28, 2026 results: revenue $10.6 million.

“United States manufacturing four types of microdisplays,” concluded Murray. First Quarter 2026 Financial Results Total revenues for the first quarter ended March 28, 2026, were $10.6 million, as compared to $10.5 million for the first quarter ended March 29, 2025. The slight year-over-year increase reflects new award and collaboration revenue contributions from the”

Global Crossing Airlines Group Inc. reported for the first quarter ended March 31, 2026 results: revenue $76.6 Million, net income $2.7 Million, EPS $0.04 per share.

“Global Crossing Airlines Reports First Quarter 2026 Financial Results Strong Aircraft Utilization and Block Hour Growth Drive 15% Year-Over-Year Increase in Revenue to $76.6 Million Increased GAAP Net Income 14x Year-Over-Year to $2.7 Million or $0.04 per Share and EBITDAR by 17% Year-Over-Year to $24.2 Million”

Connect Biopharma Holdings Ltd reported the three months ended March 31, 2026 results: revenue $0.2 million, net income $19.4 million, EPS ($0.34) per share.

“its cash and investments will be sufficient to fund operations into the second half of 2027. • License and collaboration revenues for the three months ended March 31, 2026 were $0.2 million related to the upfront license fee under the license agreement with Simcere. There were no license and collaboration revenues for the three months ended March 31, 2025. As a part”

Marygold Companies, Inc. reported the three and nine months ended March 31, 2026 results: revenue $7.2 million, net income $222,000, EPS $0.01 per share.

“Revenue for the 2026 third fiscal quarter rose 30.2% to $7.2 million, from $5.5 million last year, which included $0.6 million from the Company’s Canadian subsidiary that was sold in July 2025. Net income increased to $222,000, equal to $0.01 per share, from a loss of $1.0 million, or a loss of $0.2 per share, a year ago. For the nine months ended March 31, 2026, revenue advanced to $18.4 million from $17.9 million in the comparable prior year period, which included $1.8 million from the Company’s previously owned Canadian subsidiary. The Company’s net loss for the 2026 year-to-date period was reduced to $0.7 million, or a loss of $0.02 per share, from a net loss of $4.3 million, equal to a loss of $0.11 per share, a year ago.”

ENERGY FOCUS, INC/DE reported first quarter ended March 31, 2026 results: revenue $0.9 million, net income $0.1 million, or $(0.02) per basic and diluted share, EPS $(0.02) per basic and diluted share.

“and military maritime market (“MMM”) , today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights: • Net sales of $0.9 million increased to 54.1% compared to the first quarter of 2025, reflecting an increase of $0.2 million, or 52.1% in military sales, and an increase of $0.1 million, or 56.7% in”

Mereo BioPharma Group plc reported first quarter ended March 31, 2026 results: net income $6.7 million. Guidance reaffirmed.

“Net loss for the first quarter of 2026 was $6.7 million”

TON Strategy Co reported the first quarter ended March 31, 2026 results: revenue Total revenue was $5.3 million, net income Net loss before income taxes was $(91.0) million.

“for the first quarter of 2026 reflect the operation of its TON treasury strategy, including staking activities, alongside its legacy operating businesses. Total revenue was $5.3 million and included approximately $3.0 million from staking activities. Gross profit was $4.0 million. Total costs and expenses were $7.8 million, reflecting costs associated with”

ACCESS Newswire Inc. reported the three months ended March 31, 2026 results: revenue $5.3M, net income $0.6M, or $0.16 per diluted share, EPS $0.16 per diluted share.

“end of Q1 2026 was $12,803, up from $11,139 at the end of Q1 2025 · Q1 2026 Adjusted EBITDA remained consistent at $564,000 compared to Q1 2025 · Q1 2026 revenue decreased to $5.3M compared to $5.8M in Q4 2025 and $5.5M in Q1 2025 · Gross margin decreased to 74% compared to 78% in Q1 2025 · Cash flow from operations increased to $871,000 compared to”

Consolidated Water Co. Ltd. reported the first quarter ended March 31, 2026 results: revenue $30.0 million, net income $3.8 million, EPS $0.23 per diluted share.

“call at 11:00 a.m. Eastern time tomorrow to discuss the results (see dial-in information below). ​ First Quarter 2026 Financial Summary ● Total revenue decreased 11% to $30.0 million. ● Retail revenue decreased 9% to $8.6 million due to significantly greater rainfall on Grand Cayman during the quarter. ● Bulk revenue increased 4% to $8.7 million primarily due”

Veradermics, Inc reported the first quarter ended March 31, 2026 results: net income Net loss was $27.2 million, for the first quarter of 2026, as compared to a net loss of $12.4 million for the first quar.

“Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate and clinical progress.”

SideChannel, Inc. reported second quarter of the fiscal year ending September 30, 2026 ("FY 2026") results: revenue $1.6 million, net income $444 thousand, EPS $0.10 per share.

“companies, today announced its financial results for the second quarter of the fiscal year ending September 30, 2026 (“FY 2026”). FY 2026 Second Quarter Highlights ● Revenue of $1.6 million, representing $318 thousand, or 16.8%, less than fiscal year ended September 30, 2025 (“FY 2025”) second quarter revenue of $1.9 million. ● Gross margin of 53.5%, 380 basis”

C3.ai, Inc. reported Full Year FY2026 results: revenue Total Revenue was $250.3 million.

“Total Revenue was $250.3 million, within the Company's guidance range of $246.7 to $250.7 million.”

C3.ai, Inc. reported preliminary financial results for Q4 FY2026.

“Q4 Revenue of $51.6 Million Within Guidance Range”

STRATUS PROPERTIES INC reported first-quarter 2026 results: revenue $3.8 million, net income $6.6 million, EPS $0.82 per diluted share.

“$3.6 million, which is subject to satisfaction of closing conditions. In April 2026, Stratus sold one Amarra Villas home for $3.6 million. • Revenues for first-quarter 2026 were $3.8 million compared to revenues of $5.0 million for first-quarter 2025. The decrease was primarily due to decreased revenue from Lantana Place – Retail, which was sold in fourth-quarter”

AtaiBeckley Inc. reported financial results for the first quarter ended March 31, 2026.

“On May 12, 2026, AtaiBeckley Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026 and provided program and business updates.”

SOLESENCE, INC. reported the first quarter ended March 31, 2026 results: revenue $13.0 million, net income Net loss for the first quarter was approximately $0.8 million.

“this will position us for improved operational and financial results as we move through the year.” First Quarter 2026 Financial Highlights Revenue for the first quarter was $13.0 million, compared to $14.6 million for the same period in 2025. Gross profit in the first quarter was $3.3 million, compared to $3.4 million for the same period in 2025. Gross margin in”

Corbus Pharmaceuticals Holdings, Inc. reported first quarter ended March 31, 2026 results: net income net loss of approximately $23.0 million, EPS net loss per basic and diluted share of $1.23.

“Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update”

SPAR Group, Inc. reported first quarter ended March 31, 2026 results: revenue Net revenues were $30.5 million, net income GAAP Net loss attributable to SPAR Group, Inc. was ($553) thousand, or ($0.02) per diluted share, EPS ($0.02) per diluted share. Guidance reaffirmed.

“prudent capital allocation, with a clear focus on supporting growth while maintaining a solid balance sheet,” concluded Hennen. First Quarter 2026 Highlights ● Net revenues were $30.5 million, down 10.3% year-over-year, comprising U.S. revenues down 11.7% due to lower Remodel work, and Canada revenues up 3.0%. ● Consolidated Gross Margin was 22.3% of sales, a 90-basis”

NEUROONE MEDICAL TECHNOLOGIES Corp reported financial results for the fiscal quarter ended March 31, 2026.

“On May 12, 2026, NeuroOne Medical Technologies Corporation (the "Company") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.”

Kalaris Therapeutics, Inc. reported financial results for quarter ended March 31, 2026.

“Research and Development Expenses : Research and development expenses were $7.6 million for the quarter ended March 31, 2026, compared with $6.0 million for the quarter ended March 31, 2025.”

Imunon, Inc. reported the three months ended March 31, 2026 results: net income $4.3 million, EPS $0.84 per share.

“Net loss for the first quarter of 2026 was $4.3 million, or $0.84 per share”

Adagio Medical Holdings, Inc. reported three months ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $7.0 million.

“Net loss for the three months ended March 31, 2026 was $7.0 million, compared to a net loss of $7.7 million for the three months ended March 31, 2025.”

Alliance Laundry Holdings Inc. reported financial results for the first quarter of 2026.

“On May 12, 2026 , Alliance Laundry Holdings Inc. issued a press release providing information regarding earnings for the first quarter of 2026 .”

SunPower Inc. reported Q1 2026 results: revenue 72,793.

“from our recent 10K audit. SunPower Q1’26 Revenue & Operating Income Statement 1 GAAP 2 NON-GAAP 3 ($1000s, except gross margin) Q1 2026 Q4 2025 4 Q1 2026 Q4 2025 4 Revenue 72,793 90,985 72,793 90,985 Gross Profit 45,162 45,996 46,883 55,195 Gross Margin 62 % 51 % 64 % 61 % Operating Expense (Opex) 64,357 58,684 59,748 52,011 Opex (less commission) 35,793”

Leatt Corp reported first quarter ended March 31, 2026 results: revenue $19.51 million, net income $1.77 million, EPS $0.28 per basic and $0.27 per diluted share.

“results for the first quarter ended March 31, 2026. All financial numbers are in U.S. dollars. First Quarter 2026 and Recent Highlights · First quarter 2026 revenues were $19.51 million, up 27%, compared to the 2025 first quarter. · First quarter 2026 net income was $1.77 million, up 58%, compared to the 2025 first quarter. · Revenue growth in all major product”

NETLIST INC reported first quarter ended March 28, 2026 results: revenue $104.9 million, net income $8.6 million, EPS $0.03 per share.

“, May 12, 2026 - Netlist, Inc. (OTCQB: NLST) today reported financial results for the first quarter ended March 28, 2026. Highlights: · Net sales for first quarter of 2026 were $104.9 million, an increase of 262% compared to the first quarter of 2025. · Gross profit for first quarter of 2026 was $22.4 million, an increase of 1,622% compared to the first quarter of”

PMV Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.

“Net loss for the quarter ended March 31, 2026, was $18 million compared to $17.4 million for the quarter ended March 31, 2025.”

TENAX THERAPEUTICS, INC. reported the quarter ended March 31, 2026 results: net income $15.7 million.

“Tenax Therapeutics reported a net loss of $15.7 million for the first quarter of 2026, compared to a net loss of $10.4 million for the first quarter of 2025.”

Unicycive Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $(12.8) million loss, EPS $(0.54) per share of common stock.

“Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026”

Coya Therapeutics, Inc. reported quarter ended March 31, 2026 results: net income Net loss was $7.2 million for the three months ended March 31, 2026. Guidance reaffirmed.

“Net loss was $7.2 million for the three months ended March 31, 2026, compared to net loss of $7.3 million for the three months ended March 31, 2025.”

Sagimet Biosciences Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026, was $10.7 million.

“Sagimet Biosciences Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.”

Xilio Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $12.6 million.

“Collaboration and license revenue was $12.6 million for the quarter ended March 31, 2026, compared to $2.9 million for the quarter ended March 31, 2025.”

Mereo BioPharma Group plc reported the first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $6.7 million.

“On May 12, 2026, Mereo BioPharma Group plc announced its financial results for the first quarter ended March 31, 2026 and provided an update on recent corporate developments.”

Under Armour, Inc. reported financial results for the fourth quarter and fiscal year ended March 31, 2026.

“On May 12, 2026, Under Armour, Inc. (“Under Armour”, or the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended March 31, 2026.”

Ambiq Micro, Inc. reported first quarter 2026 results: revenue $25,060, net income $(10,171 ). Guidance raised.

“thousands) Three months ended March 31, Three months ended December 31, Three months ended March 31, Quarter over quarter change Year over year change 2026 2025 2025 Net sales $ 25,060 $ 20,744 $ 15,732 20.8 % 59.3 % Gross profit $ 10,891 $ 8,859 $ 8,389 22.9 % 29.8 % Gross margin 43.5 % 42.7 % 53.3 % 0.8 pts -9.8 pts Operating expense $ 22,580 $ 20,821 $ 17,130”

HARVARD BIOSCIENCE INC reported the first quarter ended March 31, 2026 results: revenue $20.8 million, net income $(3.4) million. Guidance reaffirmed.

“margin NPI sales growth driving bottom line growth in the second half of the year.” First Quarter 2026 Results For the first quarter of 2026, the Company reported revenues of $20.8 million compared to $21.8 million in the first quarter of 2025. Gross margin for the first quarter of 2026 was 59%, compared to 56% in the first quarter of 2025. Net loss for the first”

Vireo Growth Inc. reported the three months ended March 31, 2026 results: revenue $106.2 million.

“hereof, regardless of any general incorporation language in such filing. ​ --- EX-99.1 (EX-99.1) --- Vireo Growth Inc. Announces First Quarter 2026 Results Q1 GAAP revenue of $106.2 million increased 333.5% year-over-year, driven by recently closed M&A transactions Moves to 4 th largest cannabis company on a pro forma basis by revenue Closed the Schwazze acquisition”

ZEBRA TECHNOLOGIES CORP reported second quarter 2026 results: revenue sales growth between 14% and 17% compared to the prior year, EPS Non-GAAP diluted earnings per share are expected to be in the range of $4.20 to $4.50. Guidance raised.

“The Company expects second quarter sales growth between 14% and 17% compared to the prior year”

ZEBRA TECHNOLOGIES CORP reported full year 2026 results: EPS Non-GAAP diluted earnings per share are expected to be in the range of $18.30 to $18.70. Guidance raised.

“Non-GAAP diluted earnings per share are expected to be in the range of $18.30 to $18.70.”

ZEBRA TECHNOLOGIES CORP reported first quarter ended April 4, 2026 results: EPS Non-GAAP diluted EPS increased year-over-year to $4.75.

“Net sales of $1,495 million; year-over-year increase of 14.3%”